secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001437749-25-013236
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity presents novel DRP for daratumumab in multiple myeloma at AACR
-----------------------------------------------------------------------

- First DRP developed for an antibody therapy (daratumumab), expanding platform beyond small molecules.
- DRP identified 53 genes (27 sensitivity, 26 resistance) from in vitro data and KYDAR trial bone marrow samples.
- Predictor aims to identify multiple myeloma patients likely to benefit from daratumumab; presented at AACR 2025.
- Management highlights potential for future collaborations to bring precision diagnostics to more patients.
- Allarity's lead program, stenoparib (dual PARP/WNT inhibitor), remains in Phase 2 for ovarian cancer and small cell lung cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000143774925013236/0001437749-25-013236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000143774925013236/allr20250425_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-013236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer